In this video, Prof. Niels van de Donk of VU University Medical Center, Amsterdam, briefly discusses the multiple mechanisms of action of DARZALEX® and how the drug promotes myeloma and immunosuppressor cell death, leading to durable anti-tumour responses
View an animation that demonstrates the multifaceted mode of action of DARZALEX® – the first approved CD38-targeting monoclonal antibody for MM
MM: multiple myeloma